Grifols, S.A.
NASDAQ:GRFS · NASDAQ Global Select
+$0.03 today
Vol 0.96M · Avg 0.69M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
7.3%
avg 9.5%
ROIC
5.3%
avg 5.5%
ROA
2.0%
avg 3.1%
Analysis
ROE is currently the strongest return metric at 7.3% versus its period average of 9.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jose Ignacio Abia Buenache | Chief Executive Officer & Director | $4.08M | — | 58 | — | — |
Jorg Schuttrumpf | Chief Scientific Innovation Officer | — | — | 52 | — | — |
Roland Wandeler | President of Biopharma Business Unit | — | — | 54 | — | — |
Camille Alpi | Chief Human Resources & Talent Officer | — | — | 44 | — | — |
Daniel Fleta Coit | Chief Industrial Services Officer | — | — | 54 | — | — |
David Ian Bell | Chief Corporate Affairs & Legal Officer | — | — | 72 | — | — |
Enrique de la Torre | Chief Compliance Officer | — | — | 53 | — | — |
Jaime Gonzalez Peralta | Chief Digital Information Officer | — | — | 52 | — | — |
Daniel Segarra | Head of Investor Relations & Sustainability and Vice President | — | — | — | — | — |
Miguel Louzan | Chief Digital Information Officer | — | — | 52 | — | — |
Lluis Pons Gomez | Senior Vice President of Strategy & Chief Operating Officer Office | — | — | 42 | — | — |
Rahul Srinivasan | Chief Financial Officer | — | — | 49 | — | — |
Sergio Roura Adell | President of Commercial Tech Support | — | — | 57 | — | — |
Vicente Blanquer Torre | Chief Quality Officer | — | — | 65 | — | — |
Montse Ribas | Chief Communications and Reputation Officer | — | — | 57 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +27.1% | +5.2% (15yr)1 analysts |
| Revenue | N/A | N/A | +14.5% | +6.4% (15yr)3 analysts |
| Net Income | N/A | N/A | +27.5% | +5.2% (15yr)3 analysts |
| EBIT | N/A | N/A | +13.7% | +5.4% (15yr)3 analysts |
Analysis
Recent growth has been strongest in Net Income at +27.5% over three years. Forward estimates point to Revenue at +6.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.53B
Molina Healthcare, Inc.
NYSE:MOH
$10.33B
Globus Medical, Inc.
NYSE:GMED
$10.24B
Masimo Corporation
NASDAQ:MASI
$9.42B
Henry Schein, Inc.
NASDAQ:HSIC
$9.07B
Corcept Therapeutics Incorporated
NASDAQ:CORT
$8.84B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.10B
AptarGroup, Inc.
NYSE:ATR
$7.76B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.66B
Avantor, Inc.
NYSE:AVTR
$6.50B
Who manages GRFS?
Grifols, S.A. (GRFS) lists 15 active executives. The top listed executive is Jorg Schuttrumpf, Chief Scientific Innovation Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.